The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 20, 2019

Filed:

Feb. 16, 2018
Applicant:

Bodor Laboratories, Inc., Miami, FL (US);

Inventors:

Nicholas S. Bodor, Bal Harbour, FL (US);

David Angulo, Tampa, FL (US);

Assignee:

BODOR LABORATORIES, INC., Miami, FL (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 8/41 (2006.01); A61K 8/49 (2006.01); A61K 9/00 (2006.01); A61K 31/14 (2006.01); A61K 31/40 (2006.01); A61K 47/10 (2017.01); A61Q 15/00 (2006.01); A61K 31/205 (2006.01); A61K 31/4015 (2006.01);
U.S. Cl.
CPC ...
A61K 31/40 (2013.01); A61K 8/4913 (2013.01); A61K 9/0014 (2013.01); A61K 47/10 (2013.01); A61Q 15/00 (2013.01); A61K 8/416 (2013.01); A61K 31/14 (2013.01); A61K 31/205 (2013.01); A61K 31/4015 (2013.01);
Abstract

The subject application is directed to a method of treating hyperhidrosis in a mammalian subject comprising topically administering a composition comprising a pharmaceutically acceptable vehicle and from about 1.0% to about 25% of a compound selected from the group consisting of: (i) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(methoxycarbonylmethyl)-1-methylpyrrolidinium bromide; and (ii) 3-(2-cyclopentyl-2-phenyl-2-hydroxyacetoxy)-1-(ethoxycarbonylmethyl)-1-methylpyrrolidinium bromide; to skin of an area of a mammalian subject suffering from hyperhidosis, before bedtime, such that, compared to untreated, baseline conditions, sweat production is reduced by at least about 25% for at least about six (6) hours; and such that sweat production is reduced by an amount substantially equivalent to an amount that sweat production is reduced as compared to untreated, baseline conditions, following administration of a composition comprising the same concentration of glycopyrrolate.


Find Patent Forward Citations

Loading…